Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
BNT162b2
SARS-CoV-2
health care worker
humoral and cellular immunity
immunological memory
vaccination
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
12
2021
accepted:
07
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
9
4
2022
Statut:
epublish
Résumé
The mRNA-based vaccine BNT162b2 of BioNTech/Pfizer has shown high efficacy against SARS-CoV-2 infection and a severe course of the COVID-19 disease. However, little is known about the long-term durability of the induced immune response resulting from the vaccination. In a longitudinal observational study in employees at a German hospital we compared the humoral and cellular immune response in 184 participants after two doses of the BioNTech/Pfizer vaccine (BNT162b2) with a mid-term follow-up after 9 months. Anti-SARS-CoV-2 binding antibodies were determined using both a quantitative and a semi-quantitative assay. For a qualitative assessment of the humoral immune response, we additionally measured neutralizing antibodies. Cellular immune response was evaluated by measuring Interferon-gamma release after stimulating blood-cells with SARS-CoV-2 specific peptides using a commercial assay. In the first analysis, a 100% humoral response rate was described after two doses of BNT162b2 vaccine with a mean antibody ratio of 8.01 ± 1.00. 9 months after the second dose of BNT162b2, serological testing showed a significant decreased mean antibody ratio of 3.84 ± 1.69 (p < 0.001). Neutralizing antibodies were still detectable in 96% of all participants, showing an average binding inhibition value of 68.20% ± 18.87%. Older age (p < 0.001) and obesity (p = 0.01) had a negative effect on the antibody persistence. SARS-CoV-2 specific cellular immune response was proven in 75% of individuals (mean Interferon-gamma release: 579.68 mlU/ml ± 705.56 mlU/ml). Our data shows a declining immune response 9 months after the second dose of BNT162b2, supporting the potentially beneficial effect of booster vaccinations, the negative effect of obesity and age stresses the need of booster doses especially in these groups.
Sections du résumé
Background
The mRNA-based vaccine BNT162b2 of BioNTech/Pfizer has shown high efficacy against SARS-CoV-2 infection and a severe course of the COVID-19 disease. However, little is known about the long-term durability of the induced immune response resulting from the vaccination.
Methods
In a longitudinal observational study in employees at a German hospital we compared the humoral and cellular immune response in 184 participants after two doses of the BioNTech/Pfizer vaccine (BNT162b2) with a mid-term follow-up after 9 months. Anti-SARS-CoV-2 binding antibodies were determined using both a quantitative and a semi-quantitative assay. For a qualitative assessment of the humoral immune response, we additionally measured neutralizing antibodies. Cellular immune response was evaluated by measuring Interferon-gamma release after stimulating blood-cells with SARS-CoV-2 specific peptides using a commercial assay.
Results
In the first analysis, a 100% humoral response rate was described after two doses of BNT162b2 vaccine with a mean antibody ratio of 8.01 ± 1.00. 9 months after the second dose of BNT162b2, serological testing showed a significant decreased mean antibody ratio of 3.84 ± 1.69 (p < 0.001). Neutralizing antibodies were still detectable in 96% of all participants, showing an average binding inhibition value of 68.20% ± 18.87%. Older age (p < 0.001) and obesity (p = 0.01) had a negative effect on the antibody persistence. SARS-CoV-2 specific cellular immune response was proven in 75% of individuals (mean Interferon-gamma release: 579.68 mlU/ml ± 705.56 mlU/ml).
Conclusion
Our data shows a declining immune response 9 months after the second dose of BNT162b2, supporting the potentially beneficial effect of booster vaccinations, the negative effect of obesity and age stresses the need of booster doses especially in these groups.
Identifiants
pubmed: 35309303
doi: 10.3389/fimmu.2022.839922
pmc: PMC8931311
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Interferon-gamma
82115-62-6
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
839922Informations de copyright
Copyright © 2022 Herzberg, Fischer, Lindenkamp, Becher, Becker, Honarpisheh, Guraya, Strate and Knabbe.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Int J Obes (Lond). 2020 Sep;44(9):1832-1837
pubmed: 32712623
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Lancet Respir Med. 2021 Nov;9(11):e104-e105
pubmed: 34687656
Int J Infect Dis. 2021 Jan;102:136-143
pubmed: 33075538
Front Immunol. 2019 Apr 05;10:721
pubmed: 31024553
Diabetes Metab Res Rev. 2022 Jan;38(1):e3465
pubmed: 33955644
Lancet Microbe. 2021 Oct;2(10):e527-e535
pubmed: 34258603
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Clin Res Cardiol. 2021 Aug;110(8):1142-1149
pubmed: 34241676
Immunity. 2021 Feb 9;54(2):205-210
pubmed: 33513337
Acta Med Acad. 2021 Aug;50(2):308-316
pubmed: 34847685
Vaccine. 1994 Jul;12(9):771-2
pubmed: 7975854
Front Public Health. 2021 Sep 27;9:732787
pubmed: 34646805
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Obesity (Silver Spring). 2022 Mar;30(3):606-613
pubmed: 34850576
N Engl J Med. 2021 Sep 30;385(14):1330-1332
pubmed: 34469645
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Vaccine. 2022 Jan 21;40(2):206-212
pubmed: 34895938